2/2
![Sanofi and Regeneron present more positive data for Dupixent product](https://i-invdn-com.investing.com/trkd-images/LYNXMPEI9A06Y_L.jpg)
© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier
2/2
![Sanofi and Regeneron present more positive data for Dupixent product](https://i-invdn-com.investing.com/trkd-images/LYNXMPEI9A06Y_L.jpg)
© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier
2/2
PARIS (Reuters) – Healthcare companies Sanofi (NASDAQ:) and partner Regeneron (NASDAQ:) presented on Tuesday more positive data for their Dupixent product.
The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
Be the first to comment